Why BPC-157 Is Non-Negotiable When Running Retatrutide

The GLP-GI Problem

Every GLP receptor agonist produces GI side effects. It's not a bug — it's a direct consequence of GLP-1 receptor activation in the enteric nervous system. The data from Retatrutide Phase 2:

• Nausea: 43% incidence
• Diarrhea: 34% incidence
• Vomiting: 22% incidence

These numbers come from gradual dose escalation. Without proper escalation and gut support, the side effect profile is significantly worse.

The GLP Mechanism in the GI Tract

GLP-1 receptors are expressed throughout the gastrointestinal tract — not just the brain and pancreas. GLP-1 receptor activation:

• Slows gastric emptying
• Reduces gut motility
• Increases satiety signals

At research-level doses, these effects are significant. Gastric emptying can slow by 30-50%, creating nausea, bloating, and GI discomfort.

What BPC-157 Does

BPC-157 is a 15-amino acid peptide derived from human gastric juice (Body Protection Compound-157). It has been studied in 36+ preclinical publications, primarily by Dr. Sikiric's group at the University of Zagreb.

Key gastric mechanisms:

• NO system modulation: BPC-157 upregulates eNOS expression, increasing mucosal blood flow
• EGF receptor upregulation: Supports mucosal cell turnover and repair
• Cytoprotective against NSAIDs, alcohol, stress: Documented in multiple gastroprotection models
• No MTD found: Rodent safety studies have not identified a minimum toxic dose

The Clav Stack Protocol

Clavicular runs BPC-157 from day 1 of any GLP protocol — not as a reactive treatment but as prophylaxis. The rationale: if Retatrutide is doing what it's supposed to do in the gut (slowing gastric emptying), you want BPC-157 actively supporting gut lining integrity throughout.

Research use only.